Novacea, Inc. announced today that AQ4N, also known as banoxantrone, one of the Company's anti-cancer product candidates, was featured in four presentations at the 97th Annual Meeting of the American Association of Cancer Research (AACR) held this week in Washington D.C. These data were presented by both Novacea and its development collaborator KuDOS Pharmaceuticals, Ltd. KuDOS was recently acquired by AstraZeneca PLC (NYSE: AZN).
